Posted by Michael Wonder on 27 Apr 2021
Fractyl announces FDA breakthrough device designation for Revita DMR in insulin treated type 2 diabetes
27 April 2021 - REVITA-T2Di trial is underway to evaluate the effectiveness of Revita DMR in improving glucose control while reducing or eliminating the need for insulin.
Fractyl Laboratories today announced that the U.S. FDA has granted breakthrough device designation for Revita DMR in patients with insulin treated type 2 diabetes mellitus.
